Managed Healthcare Executive July 16, 2025
The president of the International AIDS Society (IAS) is calling for more transparency about the pricing of lenacapavir in the access agreement that Gilead Sciences has signed with The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) to supply 2 million doses of the groundbreaking preexposure prophylaxis (PrEP) medication.
In her remarks at the opening ceremony of the IAS meeting in Kigali, Rwanda, on Monday and at a press conference on Tuesday, the IAS president, Beatriz Grinsztejn, M.D., Ph.D., referenced the lack of transparency in the agreement between Gilead and the Global Fund that was announced last week.
At the press conference, Grinsztejn said that disclosure of the price is important to middle-income countries such as Brazil...
Today's Sponsors
Today's Sponsor